Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial

Rita Murri, Adriana Ammassari, Patrizio Pezzotti, Antonella Cingolani, Andrea De Luca, Federico Pallavicini, Rita Grillo, Andrea Antinori

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We assessed the incidence and determinants of bacteremia, pneumonia, and sinusitis/otitis in HIV-positive people receiving cotrimoxazole (CTX) or dapsone-pyrimethamine (DP) for primary prophylaxis of Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis (TE) within a randomized clinical trial. In total, 244 patients were randomized: 122 were assigned to CTX and 122 to DP. In the cohort, 22 bacteremia, 63 pneumonia, and 39 sinusitis/otitis cases were observed. Incidence rates of bacteremia, pneumonia, and sinusitis/otitis as well as the 2-year probability of remaining free from any bacterial infection were not significantly different between the two groups. At multivariate analysis, the risks of developing bacteremia and pneumonia were found to be independently increased by the use of a central venous catheter (hazard ratio [HR], 4.48; p <.05 and HR, 4.13; p <.01, respectively) and by hospitalization (HR, 28.82; p <.05 and HR, 10.15; p <.05, respectively). In conclusion, CTX at the dosage employed for primary PCP/TE prophylaxis does not seem to protect against bacterial infections more than second-line DP.

Original languageEnglish
Pages (from-to)49-55
Number of pages7
JournalJournal of Acquired Immune Deficiency Syndromes
Volume27
Issue number1
Publication statusPublished - May 1 2001

Fingerprint

Pneumocystis carinii
Toxoplasma
Bacteremia
Bacterial Infections
Otitis
Pyrimethamine
Dapsone
Sinusitis
Pneumonia
Sulfamethoxazole Drug Combination Trimethoprim
Randomized Controlled Trials
HIV
Pneumocystis Pneumonia
Incidence
Encephalitis
Central Venous Catheters
Hospitalization
Multivariate Analysis

Keywords

  • Bacterial infections
  • Cotrimoxazole
  • Pneumocystis carinii
  • Primary prophylaxis

ASJC Scopus subject areas

  • Virology
  • Immunology

Cite this

Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial. / Murri, Rita; Ammassari, Adriana; Pezzotti, Patrizio; Cingolani, Antonella; De Luca, Andrea; Pallavicini, Federico; Grillo, Rita; Antinori, Andrea.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 27, No. 1, 01.05.2001, p. 49-55.

Research output: Contribution to journalArticle

@article{4cc9dd7de3ee438ebf78074b10fed9e0,
title = "Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial",
abstract = "We assessed the incidence and determinants of bacteremia, pneumonia, and sinusitis/otitis in HIV-positive people receiving cotrimoxazole (CTX) or dapsone-pyrimethamine (DP) for primary prophylaxis of Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis (TE) within a randomized clinical trial. In total, 244 patients were randomized: 122 were assigned to CTX and 122 to DP. In the cohort, 22 bacteremia, 63 pneumonia, and 39 sinusitis/otitis cases were observed. Incidence rates of bacteremia, pneumonia, and sinusitis/otitis as well as the 2-year probability of remaining free from any bacterial infection were not significantly different between the two groups. At multivariate analysis, the risks of developing bacteremia and pneumonia were found to be independently increased by the use of a central venous catheter (hazard ratio [HR], 4.48; p <.05 and HR, 4.13; p <.01, respectively) and by hospitalization (HR, 28.82; p <.05 and HR, 10.15; p <.05, respectively). In conclusion, CTX at the dosage employed for primary PCP/TE prophylaxis does not seem to protect against bacterial infections more than second-line DP.",
keywords = "Bacterial infections, Cotrimoxazole, Pneumocystis carinii, Primary prophylaxis",
author = "Rita Murri and Adriana Ammassari and Patrizio Pezzotti and Antonella Cingolani and {De Luca}, Andrea and Federico Pallavicini and Rita Grillo and Andrea Antinori",
year = "2001",
month = "5",
day = "1",
language = "English",
volume = "27",
pages = "49--55",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Incidence and determinants of bacterial infections in HIV-positive patients receiving anti-Pneumocystis carinii/Toxoplasma gondii primary prophylaxis within a randomized clinical trial

AU - Murri, Rita

AU - Ammassari, Adriana

AU - Pezzotti, Patrizio

AU - Cingolani, Antonella

AU - De Luca, Andrea

AU - Pallavicini, Federico

AU - Grillo, Rita

AU - Antinori, Andrea

PY - 2001/5/1

Y1 - 2001/5/1

N2 - We assessed the incidence and determinants of bacteremia, pneumonia, and sinusitis/otitis in HIV-positive people receiving cotrimoxazole (CTX) or dapsone-pyrimethamine (DP) for primary prophylaxis of Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis (TE) within a randomized clinical trial. In total, 244 patients were randomized: 122 were assigned to CTX and 122 to DP. In the cohort, 22 bacteremia, 63 pneumonia, and 39 sinusitis/otitis cases were observed. Incidence rates of bacteremia, pneumonia, and sinusitis/otitis as well as the 2-year probability of remaining free from any bacterial infection were not significantly different between the two groups. At multivariate analysis, the risks of developing bacteremia and pneumonia were found to be independently increased by the use of a central venous catheter (hazard ratio [HR], 4.48; p <.05 and HR, 4.13; p <.01, respectively) and by hospitalization (HR, 28.82; p <.05 and HR, 10.15; p <.05, respectively). In conclusion, CTX at the dosage employed for primary PCP/TE prophylaxis does not seem to protect against bacterial infections more than second-line DP.

AB - We assessed the incidence and determinants of bacteremia, pneumonia, and sinusitis/otitis in HIV-positive people receiving cotrimoxazole (CTX) or dapsone-pyrimethamine (DP) for primary prophylaxis of Pneumocystis carinii pneumonia (PCP) and toxoplasmic encephalitis (TE) within a randomized clinical trial. In total, 244 patients were randomized: 122 were assigned to CTX and 122 to DP. In the cohort, 22 bacteremia, 63 pneumonia, and 39 sinusitis/otitis cases were observed. Incidence rates of bacteremia, pneumonia, and sinusitis/otitis as well as the 2-year probability of remaining free from any bacterial infection were not significantly different between the two groups. At multivariate analysis, the risks of developing bacteremia and pneumonia were found to be independently increased by the use of a central venous catheter (hazard ratio [HR], 4.48; p <.05 and HR, 4.13; p <.01, respectively) and by hospitalization (HR, 28.82; p <.05 and HR, 10.15; p <.05, respectively). In conclusion, CTX at the dosage employed for primary PCP/TE prophylaxis does not seem to protect against bacterial infections more than second-line DP.

KW - Bacterial infections

KW - Cotrimoxazole

KW - Pneumocystis carinii

KW - Primary prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=0035330059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035330059&partnerID=8YFLogxK

M3 - Article

C2 - 11404520

AN - SCOPUS:0035330059

VL - 27

SP - 49

EP - 55

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 1

ER -